List of Stem Cells Companies in United States - 254

4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer's disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.

7 Hills Pharma is a clinical-stage immunotherapy company developing a platform of novel, oral small molecules for the treatment of cancer and prevention of infectious diseases. Our compounds are first-in-concept allosteric integrin activators that leverage a unique mechanism of action to stabilize the cell-cell interactions required to mount an effective immune response. Our lead clinical candidate, 7HP349, is the only reported systemically safe immune stimulant that can activate both cellular and humoral immunity.

Abcepta is a biotechnology company that specializes in developing primary antibodies and custom services for research and drug discovery.

Accelerated Biosciences Corp. is commercializing human trophoblast stem cells isolated from the trophectoderm of embryos from women with ectopic pregnancies. hTSCs are ethically sourced and have immune-privileged characteristics. It is an abundant and dynamic pluripotent stem cell platform for basic research, disease modeling, toxicology, drug discovery, and cell therapy.

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

AcuraStem (acurastem.com) is a near-to-clinic, patient-based, drug development company pioneering drug discovery and ultimately how treatments are developed for neurodegenerative diseases—including sporadic ALS and FTD. Enabled by our ground-breaking iNeuroRx® technology platform - AcuraStem has discovered and is now advancing drug candidates that promise to strongly impact disease progression for most patients, including those for whom the genetic cause of their disease is unknown (i.e. sporadic ALS and FTD patients). The causes of neurodegenerative diseases are complex, and genetically defined forms of disease (e.g. C9ORF72-ALS and FTD) only account for a small percentage of cases. Thus, many scientists didn’t believe it was possible to develop a single effective treatment that could work broadly for all patients. But AcuraStem has shown with its extremely promising therapeutic programs for ALS and FTD that it can be done.

Aegle Therapeutics Corp. is a clinical-stage biotechnology company developing novel extracellular vesicle (“EV”) therapies to address rare and serious diseases and disorders with significant unmet medical needs. Aegle’s proprietary platform technology safely isolates native extracellular vesicles (“EVs”) from stem cells. These EVs carry complex assemblies of biologic molecules such as proteins and nucleic acids that can induce a wide variety of effects in recipient cells, including the promotion of regenerative healing, while reducing inflammation and modulating the immune system. Aegle’s EV therapy has the potential to treat a broad range of indications in multiple therapeutic areas, including dermatology, immunology-based diseases, protein deficient disorders and others.

Agastiya Biotech merges advanced, Eastern knowledge with rigorous Western R&D in order to deliver breakthrough innovative pharmaceuticals to the marketplace. Over 40% of all pharmaceutical drugs, including sophisticated chemotherapy and anti-viral drugs, are derived from natural plant sources. Through investigation of ancient Eastern botanical knowledge combined with high throughput and AI driven analysis, Agastiya Biotech engineers best in class novel small molecules for treatment of disease. We are leading the discovery and design of ground-breaking small molecules to revolutionize medicine and find a cure for the diseases of our time.

Agathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy. Discoveries in bioprocessing and genetic characterization and control have created an abundance of scientific possibilities that can help us all lead better lives. Our mission as the good science company is to create breakthrough products and services within a strong ethical and moral framework that benefit everyone. We believe in science that serves and have a relentless focus on serving our clients, employees, and society. For more information, please visitÂ

Ageless Biotech (ABT) is in the development of discardable, minimally manipulated umbilical tissue based regenerative medicine biologics to address all forms of Osteoarthritis via intra-articular procedures in cooperation with leading scientists and medical professionals. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives. We believe that the formation of life itself is contained within after birth tissues. ABT believes that it is morally, religiously and politically acceptable to use afterbirth materials that would be considered discardable in virtually every country. Furthermore, we believe this to be the right course to addressing problems that a vast majority of the population will face at some point during their lifespan.

AIVITA Biomedical is an Irvine, CA based company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development. These proprietary capabilities enable us to turn therapeutic discovery into reality, developing revolutionary cell-based treatments and healthcare products for the patients who need them. AIVITA is developing treatments for cancer, vision loss, and is bringing next-generation skincare formulations to consumers through its commercial product offerings.

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. The company was founded by scientists and other professionals with the goal of advancing discovery and innovation. Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge products at a reasonable cost, and providing excellent customer service in addition to the technical knowledge needed to facilitate their use. Our knowledgeable scientists and technicians are available to answer questions regarding any of our products. Over the past decade, Allele has become a reliable source for a wide variety of Molecular Biology reagents, superior fluorescent proteins, camelid derived nano antibodies (nAb), cellular reprogramming services and reagents, and immundiagnostic kits and various other products and custom services.

The mission of the Allen Institute is to unlock the complexities of bioscience and advance our knowledge to improve human health. Using an open science, multi-scale, team approach, the Allen Institute focuses on accelerating foundational research, developing standards and models, and cultivating new ideas to make a broad, transformational impact on science. Founded by philanthropist and visionary Paul G. Allen, the Allen Institute is a recognized leader in large-scale, open science research. Its research institutes include the Allen Institute for Brain Science, Allen Institute for Cell Science, Allen Institute for Immunology and The Paul G. Allen Frontiers Group. The Allen Institute believes that team science significantly benefits from the participation of diverse voices, experiences and backgrounds. High-quality science can only be produced when it includes different perspectives. We are committed to increasing diversity across every team and encourage people from all backgrounds to apply for our open positions.

Aloe Therapeutics is a biotech start-up aimed at delivering cancer cures. We have designed a therapy, termed Allo-Immunotherapy (AIM), to trigger an influx of activated immune cells to traffic to the tumor microenvironment - turning "cold" tumors "hot" and "hot" tumors "hotter." INFLAME WITH AIM.

Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing Antibody Drug Conjugates (ADCs) and natural killer (NK) cell therapies, supported by Companion Diagnostics. Our team are industry veterans with experience in both large pharma and biotechnology startups committed to transforming the lives of cancer patients.

ALSTEM is an early stage biotech company based in the San Francisco Bay Area specializing in Induced pluripotent stem cells and reprogramming technologies. Founded in early 2012 by a team of scientists with deep experience in both academic and industrial biotechnology, ALSTEM is advancing frontiers in genome editing, virus packaging, cell immortalization, and iPS cell technology.

Altucell, Inc. is a cellular engineering and biotech company backed by sound research and science focused on fulfilling a large "unmet need" in cell, molecular and regenerative therapy for treatment of Diabetes and other autoimmune and neurodegenerative diseases. The company’s proprietary and unique technology overcomes the major barriers to transplantation by a novel strategy utilizing patented micro-encapsulation technology, enabling a transplantable, cell-based therapy that avoids detection and rejection by the immune system.

At Amasa Therapeutics, we pioneer cell therapy and aim to radically improve the ways we treat the most malignant tumors. Our engineered cells are designed to revolutionize patient care and solve problems within oncology that are decades old.

American CryoStem Corporation (CRYO) is a clinical-stage biotechnology company, developing and delivering autologous (own self) regenerative therapies to treat diseases and conditions with significant unmet medical needs. We are prioritizing research targets and biological drug candidates where the disease biology is understood, and where our suite of technologies has the potential to make a difference. We are currently focused on mitigating the deleterious effects of post-concussion syndrome: https://clinicaltrials.gov/ct2/show/NCT04744051 and Long COVID/ PASC: Post Acute Sequelae of SARS-CoV-2 https://clinicaltrials.gov/ct2/show/NCT05669261 Translating Technology into Therapeutic Treatments™ Our core proprietary "end-to-end" patented technology platform consists of the “Collection-Processing-Cryobanking and Delivery to Point-of-Care” of Adipose Tissue (AT) and Adipose-Derived Mesenchymal Stem Cells (MSCs). Our Platform is configured to produce large quantities of autologous mesenchymal stem cells for treatments as needed, "on-demand". Through a single tissue collection, an autologous master cell sample is manufactured and cryopreserved for a lifetime of personalized treatments. Naturally, pure and simple.™

Animal Cell Therapies engages in research and development of stem cell treatments for orthopedic and chronic diseases in dogs.

Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans, leading to clinical candidate ART352-L. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Applied Cells, Inc., was founded in 2018 in Silicon Valley to create revolutionary solutions to cell separation and enrichment products, which increase cell separation efficiently by changing how physics is employed in the process. We are supporting industry experts in Cell Therapy Development with MARS® immunomagnetic cell separation Platform. Our innovative, column-free, immunomagnetic cell iso

Advancing Gene and Cell Product Development Through iPSC and Genome Editing Technologies Applied StemCell strives to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry to assist in the development of breakthrough therapeutic approaches to cure intractable diseases. ASC is a trailblazing CRO/CDMO committed to building a complete iPSC-Gene Editing platform for the production of iPSC-derived products for gene and cell therapy research and development. With the integration of our unique iPSC approach and IP-based site-specific large cargo insertion technology, TARGATT™, we (1) develop immune-compatible master iPS cell lines and (2) deliver large DNA fragments to pluripotent cells that have proven differentiation capabilities. We stand at the forefront of the iPSC-based therapy revolution delivering research- and GMP-grade iPSC solutions along with various downstream assay services. Current Offerings: • iPSC Cell Line Models: iPSC generation, CRISPR & TARGATT™ genome editing, differentiation • Cell Gene Product CDMO: TARGATT™ iPSC Platform for allogeneic cell therapy products/GMP iPSC reprogramming, cell banking, gene editing, and differentiation • Bioproduction: TARGATT™ CHO cell system for antibody screening and bioproduction/TARGATT™ HEK293 cell system for library/antibody screening • Animal Models: Custom and off-the-shelf CRISPR & TARGATT™ mouse models For patent licensing, business development, and investment inquiries, please contact us at info@appliedstemcell.com.

With APstem Therapeutics’ breakthrough discovery of Adult Pluripotent Stem Cells (APSCs™), we are on a mission to eradicate difficult-to-heal diseases and conquer the challenges of aging.

We are a clinical-stage biotech company dedicated to the discovery, development, and commercialization of advanced therapeutics that leverage the biological properties of human perinatal tissues and cells. All our efforts are made to support patients and help fulfill their unmet clinical needs.

Aruna Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders. We are leveraging our proprietary exosomes and manufacturing platform to create synergistic therapies by enhancing our exosomes with small molecules, RNA, oligonucleotides and antibodies.

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

Asymmetrex® is a life sciences biotechnology company with a focus on innovating adult stem cell medicine technology that will advance the potential of adult tissue stem cells into routine medical practice.

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

AventaCell BioMedical Co., Ltd. ("AventaCell") is among the world leaders devoted to developing novel human-derived products for use in cell culture and tissue regeneration. Helios Bioscience is AventaCell's product family brand for their products to be used in cell culture and tissue regeneration. AventaCell technologies used in the Helios Bioscience line offer new human-derived solutions for use in translational research of cell and tissue-based therapies to meet the need for animal serum-free cell expansion and production. The demand for safe, efficient and cost-effective cell expansion and production is rapidly increasing with the growth in cell therapy and regenerative medicine research and clinical development. Helios Bioscience products are designed to support expansion and production of a broad range of cells including mesenchymal stem cells and multiple immunocell lines. AventaCell is committed to providing animal serum-free products to accelerate the research, development and commercialization of safe and efficacious cell and tissue-based therapeutics.

AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 triggers the production and release of endogenous gamma delta+ Natural Killer T cells and could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology. The company is committed to developing products that improve outcomes without additional suffering because side effects from treatments should never be worse than the diseases themselves.

Bimini Health Tech houses a diversified range of medical devices and regenerative therapies, with a portfolio that includes Puregraft®, Healeon®, Dermapose® and Kerastem®. The company develops and commercializes innovative products that are elegant in their simplicity, yet impactful and proven in their aesthetic, reconstructive and therapeutic benefit. Founded in 2013, Bimini has been providing targeted bio-therapeutic solutions in aesthetic and regenerative medicine.Bimini Health Tech is headquartered in Plano, TX with sales and distribution worldwide.

BioCentriq is a premier contract development and manufacturing organization (CDMO) dedicated to advancing cell therapy. Since 2019, the company has specialized in GMP autologous and allogeneic cell therapies, offering end-to-end clinical-to-commercial capable services tailored to clients’ unique needs. Operating from two state-of-the-art U.S.-based facilities, BioCentriq provides a comprehensive range of services, including technology transfer and new technology evaluations, process and analytical development, cGMP manufacturing, quality control lot release, and stability studies. The company’s expertise spans diverse cell therapy modalities, such as T-cell (CAR-T, TCR), NK-cell, iPSC, and MSC-based products. With its proprietary LEAP™ manufacturing platform, BioCentriq accelerates service timelines while offering standardized and customizable solutions, including traditional fee-for-service, hybrid and person-in-plant operations, dedicated cleanroom capacity, and flexible service and contract arrangements. In addition to its technical capabilities, BioCentriq operates the Cell and Gene Therapy Experiential Learning Center, a training facility which provides hands-on and virtual instruction under the guidance of industry-experienced instructors and subject matter experts. The program has trained hundreds of participants, hosted major pharmaceutical companies, and integrates next-generation technologies and concepts into its curriculum including: Industry 4.0 and Lean principles, predictive analytics, augmented reality, and electronic batch record systems. Backed by GC Corporation, a South Korea-based leader in the healthcare, pharmaceutical and biotechnology industry, BioCentriq combines global expertise with a flexible working relationship, set to empower clients to develop and deliver cutting-edge, personalized therapies with unmatched precision and efficiency.

BioLegend develops antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA.

Pioneered by accomplished business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide. Leveraging advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation, this biotech company is committed to optimizing the process and technology around viable human organ replacement, and making it a safe, accessible, commercially viable, and cost-effective reality.

BioPAL is a biotechnology company that provides novel diagnostic tools to the life science community.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Biostage is a biotechnology company that focuses on developing organ replacement therapies using cellular scaffolds and tissue engineering.

Bloodworks Northwest is an independent, community-based nonprofit organization with a tradition blending volunteerism, medical science, education and research to advance transfusion medicine and improve patient care. A recognized leader in transfusion medicine, Bloodworks serves patients in nearly 90 hospitals and clinics in the Pacific Northwest and provides tissue and transplantation support to 185 hospitals across the Northwest. Patients with leukemia, cancer, burns, hemophilia and traumatic injuries also depend on Bloodworks research. With your help, we're bettering our community drop by drop.

bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company’s product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine. Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us via LinkedIn or our website to learn about rewarding career opportunities.

BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patient’s own T cells for the particular molecular fingerprint of each patient’s own cancer through our novel TCXpress technology. Our proprietary TCXpress platform is an elegant, rapid approach that exploits the patient’s own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects. The platform and implementation allows us to deliver rapid, personalized T cell treatments for a variety of cancer indications.

Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.

BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm’s proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating good safety and tolerability profiles and strong efficacy signals. We also finalized a Phase 3 randomized, double-blind, placebo-controlled clinical trial at multiple US sites, supported by a $16 million USD grant from the California Institute for Regenerative Medicine (CIRM) and another grant from the ALS Association. Currently, we are planning a Phase 3b clinical trial of NurOwn® in ALS under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). For more information, visit www.brainstorm-cell.com

Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.

We are an ISO 13485:2016 Certified Manufacturer developing innovative media formulations for cell cryopreservation, cell culture, and cell handling in cell therapy, gene therapy, and regenerative medicine. We deliver high-quality products with batch-to-batch consistency and rigorous quality controls from raw materials to final product release. We offer manufacturing services, scientific assistance in media formulation, and optimization of existing formulations to meet your specific needs.

• The Cedars-Sinai Biomanufacturing Center (CBC) is a new 25,000 square feet, state-of-the-art biomanufacturing facility located in West Hollywood, California. • Manufacturing the next generation of cell and gene therapies for human IND-enabling clinical trials. • cGMP cell manufacturing facility housing multiple cleanroom cell production suites and process development laboratories. • Combined expertise in a cGMP-compliant approach to manufacture cells at scale with innovative technologies and equipment. • Transferring laboratory protocols to cGMP, up-scaling of processes and achieving Food and Drug Administration standards to bring innovative cell therapy solutions to researchers and translational scientists. • World-class expertise in stem cell (iPSC) biology, gene editing and bioprocessing. • Supporting California Institute for Regenerative Medicine (CIRMN) programs, CBC is providing a much-needed cell biomanufacturing center in California

Celetrix is the leader in electroporation with our new high efficiency electroporation technologies for delivering DNA, RNA and proteins to cells. Celetrix provides technology and support for CAR-T manufacturing by transposon mediated expression and RNP mediated gene editing for T cells, stem cells and CD34+ HSC.

Global Leadership in Primary Cells: Excellence in cell isolation, 3D bioprinting, tissue engineering, 3D cell models, stem cells, optimized culture media and more. CAI's products and custom services support basic life science research and biopharmaceutical drug discovery. Our Center for Primary Cell Innovation pushes the edges of technology, with regular advancements developed in collaboration with academic & industry experts.

About Us: Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for human disease treatment. The company utilizes a ‘plug-and-play’ proprietary platform technology that transforms universal ‘non-gene-modified’ donor blood stem cells from umbilical cords, to produce high-quality, pure and potent, multiple clinical grade cells at scale. This innovative method aims to make stem cells and its derived therapies more accessible and efficient. Its lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with available therapies, particularly acute leukemia and myelodysplasia. The lead pre-clinical stage product is a first-in- class ‘one-size-fits-all’ cell-based cancer vaccine, composed of dendritic cell type 1 (cDC1) to circumvent the barriers in solid cancers. Platform Technology: The company's platform technology is what makes it innovative and unique. It's "Cell BioEngineMAP" is a cutting-edge platform for developing multiple cell therapy assets, leveraging the remarkable potential of universal umbilical cord-derived blood stem cells. These cells serve as a foundational source, which we can expand, differentiate, and de-differentiate using our proprietary chemical reprogramming methods to produce pure, powerful rare cell states, at large scale for clinical applications. Complementing this, our "Cell BioEngineAI" platform employs artificial intelligence to predict donor availability and target characteristics, ensuring the safety and efficacy of HLA-compatible therapies. Our goal is to create a ready-to-use, 'off-the-shelf' cell bank with therapeutic products that cover over 85% of the population, available at selected blood centers. For more information, visit www.cellbioengines.com and follow us on www.twitter.com/cell_bioengines

Cell Biolabs, Inc. proudly develops and commercializes innovative technologies and tools for life science research. We are committed to providing the best products that facilitate discovery of the mechanisms underlying cell function and disease. Our unique, cutting-edge products are currently used around the world in the research laboratories of universities, government institutes, biotechnology and pharmaceutical companies

Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.

Cell Line Genetics, Inc,(CLG) is the leading independent provider of multi-species Quality Assurance services and products for the Regenerative Medicine market. Headquartered in Madison, Wisconsin and with offices in New York City, CLG's clients include leading universities and research institutes, as well as biotechnology and pharmaceutical companies. For a complete list of CLG products and services please visit www.clgenetics.com.

Cellomics Technology, LLC is dedicated in developing more efficient and powerful tools to enhance and accelerate life science researches. Top scientific excellence is the goal and focus of our scientists.

Celltex Therapeutics Corporation is a Houston, Texas-based biotechnology company focused on spearheading breakthroughs in regenerative medicine using adult, autologous Mesenchymal Stem Cells (MSCs).

Cell X is pioneering a revolution in cell processing. At the core of this revolution lies our transformative Celligent platform – an innovative bundling of automation, imaging, data analytics, and machine learning that enables therapeutic researchers to develop consistent, reproducible, and scalable GMP-compliant processes for stem cells and bio-fabrication. Celligent enables the development of safe and effective products by executing the necessary process development and cell manufacturing procedures in a fully documented, compliant way. Successful cellular therapies demand starting with optimized cell sources; and intrinsic variability and heterogeneity among cell sources presents a major challenge. This critical first step of control over starting materials demands the use of quantitative and reproducible standards for cell and clone selection and process management based on critical process parameters (CPPs) in order to achieve products with defined critical quality attributes (CQAs). Backed by a highly experienced team, Cell X automates cell processing in diverse cell culture applications spanning mesenchymal stromal/stem cells (MSCs) and exosomes, induced pluripotent stem cells (iPSCs), hematopoietic stem cells (HSCs), connective tissue progenitor cells (CTPs) and tumor-infiltrating lymphocytes (TILs) as well as other progenitor cell types. We are dedicated to advancing the promise of cellular therapies for innovators and patients alike, ultimately making cell therapies more accessible to millions of patients worldwide. 

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. Century Therapeutics, Inc. has a research collaboration with Outpace Bio, Inc. for CAR engineering. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Chrysalis BioTherapeutics, Inc. is a privately held biopharmaceutical company developing regenerative drugs that mimic the body’s natural signals to activate endothelial progenitor cells and stem cells to stimulate tissue repair and restore normal tissue function. Chrysalis BioTherapeutics was incorporated in Delaware in 2012 to develop innovative peptide therapeutics to save lives and improve life’s quality. Chrysalis’ lead drug candidate, TP508, was initially developed to accelerate healing of dermal and musculoskeletal injuries. It proved to be especially effective in promoting healing of diabetic foot ulcers in early human clinical trials and is under development as a treatment for mass casualty injuries and burns. Chrysalis has demonstrated that TP508 mitigates effects of radiation exposure. Chrysalis is therefore collaborating with US government agencies to develop TP508 as a nuclear countermeasure to combat acute and delayed radiation syndromes and to mitigate damaging effects of brain cancer radiation therapy.

Cimeio Therapeutics is a biotechnology company based in Massachusetts, specializing in gene editing, cellular, and immunotherapy. The company focuses on developing Shielded-Cell & Immunotherapy Pairs (SCIP), which are innovative immunotherapies aimed at treating serious diseases such as genetic disorders, hematologic malignancies, and severe autoimmune conditions. Cimeio's proprietary technology platform enables the discovery of novel protein variants that help cells maintain their function while resisting depletion from targeted immunotherapies. Their core products combine modified cell surface proteins with immunotherapies, ensuring the preservation of healthy cells during treatment. Additionally, their Cell-Shielding Technology protects hematopoietic stem cells from immunotherapy-induced depletion, allowing for effective treatment of diseased cells. Cimeio has formed significant partnerships, including a collaboration with Kyowa Kirin to develop novel cell therapies and a research partnership with the University of Pennsylvania to enhance their immunotherapy research capabilities. The company has received recognition for its innovative approach, with features in publications like Forbes and research published in Nature.

One of the few FDA-licensed cord blood centers in the U.S., the Cleveland Cord Blood Center (CCBC) collects, processes, stores and distributes stem-cell rich umbilical cord blood for transplantation in patients with life-threatening disorders.

COARE Biotechnology is a multidisciplinary drug development company that seeks to advance the current treatment modality of patients with aggressive cancers by coordinately targeting aspects of both the primary tumor and the biological processes that effect metastatic initiation and progression. Our team has garnered worldwide acclaim for their groundbreaking scientific discoveries in support of the novel therapeutic platforms developed here at COARE Biotechnology. We have identified key components within cancer biology that have not been targeted – until now.

The science of genetics. The business of discovery. Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

Working on turning stem cells into human eggs

CoRegen is leveraging its groundbreaking master gene regulator platform to develop a broad range of therapeutics capable of controlling numerous genes throughout the body, with lead indications in solid tumors.

Creative Bioarray uniquely pioneers the development of high quality tissue, antibody, protein and cell array technology to efficiently analyze the concurrent expression and function of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction from a single biological sample. Creative Bioarray is a well-recognized service provider propelled by integrity, expertise and the desire to contribute to simplify, improve, and accelerate research speed of the scientists by providing the highest standard quality research products and services. Since it founded, Creative Bioarray had recognized that an important obstacle to make development of basic bioscience and preclinical researches using human specimens is the lack of access to reference materials. Consequently, Creative Bioarray was determined to be the first commercial entity specialized in building up the largest tissue-sharing platform by integrating the detailed clinical information of all the tissue samples.

Creative Medical Technology Holdings, Inc., formerly Jolley Marketing, Inc., is a clinical-stage company. The Company conducts its business operations primarily through its subsidiary, Creative Medical Technologies, Inc. (CMT). The Company is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility, miscarriages and related issues. CMT focuses on completing the testing of its erectile dysfunction (ED) treatment and, if warranted, marketing treatment kits under the name Caverstem to physicians for use with their patients suffering from ED. CMT also intends to test and, if warranted, market licensed stem cell products under its infertility technology license. Procedures for use of the Company's ED stem cell treatment consist of a one-hour out-patient visit in a physician's office. The physician would harvest a patient's bone marrow from the hip using local anesthetic and separate the stem cells using a cell separator.

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Curtana Pharmaceuticals is a privately-held, preclinical-stage biopharmaceutical company developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system (CNS) for the treatment of glioblastoma (GBM) and other brain cancers.

CytoTronics is commercializing technology emerging from the Harvard University labs to bring unique insights to drug discovery. A revolutionary approach to studying cell biology, powered by microchips.

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive Flex-NK™ bispecific antibody and iPSC-derived, TALEN® gene-edited NK-cell platforms. FLEX-NK™ bispecific antibodies are built on a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology. The company is also developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. ​ These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as relapsed multiple myeloma. Clinical studies are expected to initiate in 2023.

Our mission is to improve the way we grow cells for stem cell R&D and cultured meat production. We care about making a positive impact in reducing animal dependency for lab reagents and eventually for food as well. Defined Bio's journey starts with transforming stem cell growth medium by understanding the most critical stem cell research needs - cell growth quality, cost, and ease of use. To meet the growing demands of various customer segments, we realized that we would have to optimize all of the fundamental ingredients of defined, animal free growth media: growth factors, proteins, buffers, and growth/differentiation analysis. We have developed innovative reagents across traditional recipes, leveraging published and optimized recipes from leaders in the field. The result is exceptional reagents, media, and protocols that will materially improve quality and reduce the cost of growing stem cells and iPSC derived cells.

Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.

Direct Biologics is a market-leading innovator in regenerative medicine.

DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.

Diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, and cell and gene therapy.

At Editas Medicine, we are pioneering the possible. Our mission and commitment is to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable genomic medicines for many diseases.

Elixirgen Scientific is a global leader in regenerative medicine and biotechnology, headquartered in the Science + Technology Park at the Johns Hopkins Medical Campus in Baltimore, MD. Our mission is to advance science and medicine with fast, functional, and scalable induced pluripotent stem cell (iPSC) differentiation products and services. Our state-of-the-art, transcription-factor-based technology allows you to overcome the high cost and inefficiencies associated with lengthy cell differentiation periods. We empower research institutions, pharmaceutical organizations, and biomedical enterprises worldwide, even those with no previous iPSC experience, by increasing access to relevant cells for modeling human biology and accelerating the path to drug discovery and development. This commitment to innovation and efficiency underpins our goal to revolutionize regenerative medicine. We are the partner of choice for supplying high-quality, reliable iPSC-derived cells and kits and conducting customized research services. Connect with Elixirgen Scientific today to discover how we can accelerate your research!

Elixirgen Therapeutics is a biotechnology company advancing its controllable self-replicating RNA technology to develop therapies for a broad spectrum of diseases, including rare diseases, aging-related disorders, and cancer. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore.

Encellin is a biotechnology company specializing in cell encapsulation technology for cell-based therapeutics. The company's initial pipeline focuses on endocrine disorders with a clear mechanism of action, particularly focusing on Hypoglycemia. Encellin was founded based on the technology developed in the lab of Dr. Tejal Desai at the University of California in San Francisco.

EpiBone is a revolutionary bone reconstruction company that allows patients to "grow their own bone". EpiBone's pioneering technology utilizes a scan of the patient's bone defect and the patient's own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.

Epirium is a clinical-stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue function, potentially resulting in novel therapeutic approaches to currently intractable neuromuscular diseases. The company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration. Epirium is currently planning clinical trials with its initial drug candidate in Becker muscular dystrophy

EriVan Bio is a biotechnology company that focuses on innovating and delivering products and services related to exosome technology for molecular and cell biology research, regenerative medicine, and drug delivery.

Eterna Therapeutics is developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. We and our strategic partners are advancing innovative nucleic acid and cell therapies that offer the hope of radically improving the health outcomes of patients with high unmet medical needs. We are committed to creating a world in which patients and their families have access to effective, life-changing treatments for serious illnesses.

Everlum Bio is pioneering a novel approach to drug development for rare diseases. As opposed to working on a single disease we are doing "Drug Development as a Service". We are relentlessly focused on innovating the drug development process. Ultimately we believe this approach will usher in a personalized/precision medicine revolution.

Factor Bioscience develops new technologies in a little-explored area that we believed had enormous potential: messenger RNA ("mRNA").

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.

FibroBiologics is the world leader in cell therapy using fibroblasts to regenerate tissue and cure chronic diseases. Currently, FibroBiologics holds 150+ U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, and Cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.

Founded in 1990, Telethon Italy is one of the biggest biomedical charity in Italy, whose mission is to advance biomedical research towards the diagnosis, cure and prevention of muscular dystrophies and other human genetic diseases. Telethon Italy focuses on scientific research and does not offer healthcare, material assistance to patients and families or advocacy. Since 1991, Telethon Italy has invested 394 million Euros in research and funded 2,477 research projects on more than 445 human genetic diseases, which range from basic research to clinical trials.

FOXG1 Research Foundation (FRF) is a US-based 501(c)(3) not-for-profit dedicated to accelerating research to find a cure FOXG1 syndrome. Previously called Brain Factor 1, FOXG1 is one of the first and most fundamental genes formed during brain development. Most children with FOXG1 syndrome cannot walk, talk, crawl, or take care of their most basic needs; most have a feeding tube, most undergo major surgeries, and most suffer from life-threatening seizures. Many leading neuroscientists believe that FOXG1 holds the key to unlocking many brain disorders that affect millions of people including autism, schizophrenia, Alzheimers and brain cancers. They also believe FRF can get to human clinical trials in three to five years. The FOXG1 Research Foundation was founded by FOXG1 moms in 2017 with the support of a worldwide team of FOXG1 parents. FRF is quickly becoming known in the biotech arena as a Patient Organization making tremendous strides. FRF raised more than one million dollars in less than one year and has successfully funded six major research projects fostering the most comprehensive study of FOXG1 to-date. The potential to improve millions of lives is tremendous. The time is now. Join us to pioneer some of the most ground-breaking research in human history. 1 www.foxg1research.org

Fujifilm Cellular Dynamics, Inc. develops and manufactures biologically relevant human cells derived from induced pluripotent stem (iPS) cells. Our iCell® and donor-specific MyCell® Products are highly pure, highly reproducible, and available in industrial quantity to enable drug discovery, toxicity testing, stem cell banking, and cell therapy development.

GABAeron, Inc. is a biopharmaceutical company focusing on the development of therapies using stem cells and small molecules to treat neurological diseases. GABAeron takes a novel approach that combines precision medicine (using genetic information for patient stratification) with regenerative medicine (using human iPSC-derived cell products for therapy) and pharmacological intervention (small molecules). The therapeutic programs of GABAeron are specifically designed to replace or protect some of the most vulnerable brain cell populations to restore and preserve brain functions with human iPSC-derived cell products and small molecules in patients with genetically defined neurological diseases.

Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. We aim to change that. Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, we have developed a platform to produce female reproductive cell lines. We use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Our team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Our first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.

Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com

GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church's lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

Gene Biotherapeutics is a biotechnology company that focuses on the clinical development and commercialization of DNA-based biotherapeutics for the treatment of cardiovascular disease.

GeneCure Biotechnologies is a biotechnology company that focuses on developing gene therapy based technologies to treat genetic and acquired human diseases.

Gift of Life Marrow Registry facilitates blood stem cell and marrow transplants for children and adults battling life-threatening diseases, including leukemia, lymphoma, sickle cell and other genetic disorders. Gift of Life is a leading national bone marrow and stem cell registry that serves patients all over the world seeking donors for transplants. It was founded during the grass roots efforts to save the life of New Jersey leukemia patient Jay Feinberg, and has grown to become a leading global registry. Gift of Life is accredited by the World Marrow Donor Association, and is an affiliate donor registry of the National Marrow Donor Program and participant in the international Bone Marrow Donors Worldwide registry. Gift of Life added an in-house apheresis center in 2019 and cellular therapy laboratory in 2020, ensuring its commitment to quality and consistency every step of the way.

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, let's transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.

HebeCell was founded in 2016 by a group of scientists who wanted to push research in regenerative medicine and immuno-oncology farther than ever before. Our team of researchers includes multiple world-leading experts in stem cell biology, as well as experienced entrepreneurs and business developers. We operate a fully-equipped, state-of-the-art laboratory in Natick, MA, one of the world’s largest biotech hubs. Since 2016, we have grown HebeCell into a leading innovator in our field. Most importantly, we have developed and patented a method of producing allogeneic natural killer (NK) cells indefinitely from induced pluripotent stem cells (iPS cells) by suspending them in a liquid solution within specially engineered bioreactors. No other company or lab has this technology or these capabilities.

Helocyte, Inc. (“Helocyte”), a company founded by Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”)

Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.

HIBM (Hereditory Inclusion Body Myopathy) is a progressive and debilitating muscle wasting disorder caused by a gene defect. It touches those betwen the ages of 20 to 40 and, although progression is slow, it typically leads to total disability within 10-15 years. HIBM Research Group is laboratory funded byARM (the Advancement of Research for Myopathies,a leading supporter in research toward the cure).

HighPassBio, an ElevateBio portfolio company, is working to advance a novel approach to treating hematological malignancies by leveraging T cell receptor (TCR)-engineered T cells, known as TCR T cells. The company’s lead program is designed to treat or potentially prevent relapse of leukemia in patients who have undergone hematopoietic stem cell transplant (HSCT). The technology was born out of Fred Hutchinson Cancer Research Center by world renowned expert, Dr. Marie Bleakley.

ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation.

ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackle solid tumors. Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with the ability to differentiate into cell types including NK cells, T cells and macrophages. Pipeline In the near term, our goal is to validate the economic and clinical benefits of our expansion technology by taking an expanded-HSC-derived NK cell to clinical trials for hematological malignancies. In the long term, our unique access to the modified and unmodified immune tree allows us to tackle the challenge of solid tumors with combinations of modified cells. Agile Discovery This agile and flexible allogeneic platform reduces costs of discovery and manufacturing, expanding commercially viable indications for cellular immunotherapy. Starting from cord blood has speed and cost advantages over iPSCs, including the ability to quickly match HLA types to target populations or select beneficial genotypes without the need to edit those features into a clonal iPS line. This enables rapid iterations of abundant and consistent sources of therapeutic cells.

Immunis Inc. is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health. With age, every person experiences a reduction of factors which benefit immune system development, modulation, and health; our technology allows replacement of those factors. Our investigational product is all natural, all human, and represents a perfectly balanced set of immune modulators in naturally occurring relevant physiological concentrations. Immunis' first clinical trial is a Phase 1/2a study of the effectiveness of STEM in treating muscle atrophy, which every person experiences with age.

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic. For more information about the Company and its programs, visit www.IN8bio.com.

INCELL manufacturesand develops effective treatments for unmet medical needs.

InGel Therapeutics is Harvard-spinoff, regenerative medicine biotech leveraging novel neuroprotective mechanisms to stop retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities which include Dry-AMD and Glaucoma.

International Stem Cell Corporation (OTCBB:ISCO) develops a powerful new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection. Parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpSC) that can be “immune-matched” to millions of persons of differing sexes and racial backgrounds. A relatively small number of hpSC lines could provide sufficient immune-matched cells to cover large parts of the world’s population. ISCO plans to create a bank of these valuable hpSC lines (UniStemCell™) to serve all populations across the world. Human parthenogenetic stem cells have great therapeutic potential, yet do not require viable human embryos, thus avoiding ethical issues. ISCO’s scientists are focused on using hpSC to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells. ISCO advances and operates three businesses: Lifeline Cell Technology, Lifeline Skin Care and Universal Stem Cell Bank.

Invitrx Therapeutics, Inc. is a biotechnology company specializing in the culture and engineering of adult stem cells by which we develop innovative products and therapies that are used in aesthetics, wound closure, and healing as well as plastic and reconstructive surgery. Invitrx was founded in July 2003 by Habib Torfi following many years of research and clinical trials involving adult stem cell technology. The research was originally developed to treat patients suffering from burns, diabetic ulcers, ocular surface disorders, and other ophthalmic conditions. Methods were developed to harvest and concentrate stem cells, providing the bases for Invitrx's cytokine and growth factor technology that demonstrated remarkable results in anti-aging by reducing the appearance of blemishes, fine lines, and wrinkles. Thus, using Invitrx stem cell core technologies, the ReLuma skin, hair, and lash therapy product line was created. ReLuma cosmetic products were designed utilizing adult stem cell technology to rejuvenate and reactivate dormant cells. The entire line of ReLuma products, including hair care, are formulated with human adult stem cell conditioned media containing cytokines and growth factors (along with interleukins and matrix proteins) to help reduce signs of aging and promote a youthful, even-toned glow.

IO Biosciences develops allogeneic, gene modified cell therapies that treat cancers. Leveraging a proprietary lifesaving gene editing system and cell source, we create a unique opportunity to develop and manufacture of-the-shelf gene modified cell therapies. Taking vision from concept to reality - literally starting as a virtual, home-based biotech start-up last year, IO Biosciences has evolved to a team of 5 with office space and lab facility. Our state of the art CRISPOR gene editing methods create a new generation of universal “plug and play” cell sources for research and gene modified cell therapies treating cancers. This innovative system allows current personalized therapies to be transformed into manufactured off-the-shelf treatments and will greatly improve patient access at a competitive price point.

IPS HEART is the first induced pluripotent stem cell company to launch in 2014 around heart disease. With over $20 million+ of funded research, we were the first to publish our moon-shot approach showing extensive heart regeneration after heart attack with over 50%+ EF improvement vs control and a 70% reduction in fibrosis. We have created extensive new functional human heart muscle in our published studies thus validating our patented IPS small molecule platform approach. With a completed FDA PRE-IND meeting and GMP manufacturing, we plan to file the first IPS IND to start clinically in the United States.

iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, iTOL-100, we are advancing a pipeline of programs using both allogenic pancreatic islets and stem-cells that have the potential to cure diseases. Our lead program, iTOL-101 is being developed for Type 1 Diabetes and in a preclinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows a potentially inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need.

JangoBio is developing regenerative therapies to reverse hormone imbalances associated with aging and thereby mitigate the risk of developing a wide range of age-related diseases. Pharmaceutical treatments, such as hormone supplementation, do not address the underlying loss of function, and can have significant side effects.

Jasper Therapeutics is a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases. Their mission is to make a significant difference in the lives of patients suffering from these conditions.

Jointechlabs is a regenerative medicine company that offers point-of-care medical devices enabling safe and cost-effective non-surgical treatments.

Juvena Therapeutics is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions.

Kairos Pharma is focused on developing cutting-edge therapeutics for cancer patients that reverse the inhibitory effects of cancer on the immune system. By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life.

Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. KALA BIO is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye. KALA BIO’s biologics-based investigational therapies utilize KALA BIO’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA BIO’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA BIO is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA BIO, please visit www.kalarx.com.

Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders.

Corneal Surgery Devices

Khloris Biosciences is a private biotechnology company located in the San Francisco Bay Area. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells (iPSCs) for drug discovery, vaccine and cell therapies.

Since 2012, we are a biotechnology company developing MSC exosome products for research and therapeutic purposes. We have focused on regenerative medicine and aesthetic applications by producing quality assured, GMP grade, purified nanovesicles in a 27,000 sq ft facility in Miami, Florida.

Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible. The North America organization includes three offices in New Jersey and California that focus on drug discovery, product development, and commercialization. Together, we work as a collaborative team to understand clinical needs and advance innovations that have a profound impact on patient lives. Our growth in North America relies on entrepreneurial team players who are willing to share their expertise and ideas in an environment that prioritizes innovation, diversity, integrity and “wa.” Each person plays a significant role in shaping the work we do and the results we deliver.

Life-saving therapies. Critical diagnostics. Breakthrough clinical trials. Life Couriers places hope in the hands of patients everywhere by being the world's most trusted logistics partner for crucial pharmaceutical and medical products. We are the worldwide market leader for radiopharmaceutical and stem cell logistics. We have taken this experience with the most time-critical shipments in the world to expand our services to biopharmaceuticals, cell and gene therapies, lab specimens, clinical trials, organ transplant, medical devices, and more. We understand a fundamental reality - that missing a delivery can mean losing a life. That is why we have intentionally curated our culture to be solely focused on patient outcomes. Our people care more and they are deeply committed to enhancing, enriching, and saving lives through the power of logistics. We are Life Couriers. Logistics for Life.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com.

(Formally Caladrius Biosciences; NASDAQ: CLBS) Lisata Inc., (LSTA) a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.

We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. We are currently conducting Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS), which is the current exception to our focus on aging. Our mission is to advance Lomecel-B™ and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Our philosophy is that healthy aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging – a period known as healthspan. As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that Lomecel-B™ addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.

Your Dreams START HERE! Explore more than 180+ hands-on career programs ranging from animation to welding. Start your degree here and consider our dozens of direct college transfer options. Or simply take a class for fun! Our campuses are located throughout Madison, Fort Atkinson, Portage, Reedsburg and Watertown. Many classes and some entire degrees can be completed online from anywhere! Find flexible, affordable education that fits your life and goals. Our 93% job placement rate is proof that employers hire our graduates! If you are a jobseeker, consider applying to join the team. Our culture, benefits and rewarding roles make Madison College one of the premier employers in the Madison area. Our online communities provide a convenient place where current and prospective students, alumni, jobseekers and the community can easily connect and discuss topics related to Madison College. We want you to participate and encourage lively discussion while following a few house rules: -Be respectful. -Be honest. -Respect copyright and fair use. -Derogatory comments, including racially or sexually motivated, and sexually explicit materials are not permitted. -Follow the social media platform’s Terms of Use Agreement. -We reserve the right to remove content. Rules of Engagement Madison College is committed to providing a safe space for every member of our community. To do this, we monitor our social media accounts and will remove comments that are blatantly harmful (i.e. racist, misogynist, homophobic, transphobic) to underrepresented communities. We do not condone censorship, but as a public institution we will always err on the side of protecting the physical and mental well-being of our community members.

MAX BioPharma is a California-based biotechnology firm developing novel small molecule lipids, referred to as oxysterols, as candidates for therapeutic drugs for debilitating and fatal human diseases. These oxysterol molecules belong to the family of sterols that have the ability to stimulate bone growth, block the growth of cancer cells, and inhibit their ability to metastasize. The company is a pioneer in this new field of Oxysterol Therapeutics® and focused on translating our key science into use for two large unmet medical needs: bone formation (in fracture repair, bone tissue engineering, and osteoporosis) and cancer.

MediCell Technologies (MCT) believes that stem cells can bring unique and exceptional value to health care.We forms Strategic Partnerships with industry and academia entities to facilitate and accelerate preclinical development of stem cell therapies. We are working to advance the field of stem cell applications. Progenitor Biologics®, LLC and AT Scientific, LLC are wholly owned subsidiaries of MediCell Technologies DefenAge® is a brand of Progenitor Biologics.

MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model of weight gain in human fat cells in vitro. Our core technology enables discovery of therapeutic targets and leads, while reducing the time and money required for efficacy screening. It efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes of mature fat cells in adults. Changes in fat cell size are how adults gain (or lose) weight, and increased fat cell size predicts diabetes better than obesity per se. The products we develop will treat obesity and diabetes by shrinking fat cell size and by preventing compromised metabolism in enlarged cells. We differentiate ourselves from existing therapies (e.g. GLP-1 analogs, SGLT2 inhibitors, anorexiants, intestinal lipase inhibitors, insulin secretagogues) by focusing on adipocyte-intrinsic mechanisms of action enabled by our core technology.

Metro International Biotech, LLC is a privately-owned clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary drugs for the treatment of various diseases.

Microtissues® is a privately held company advancing technologies and applications of 3D cell culture. The company's products stand above the rest because they are designed to create more natural and more reliable 3D cell culture environments based on cell-to-cell interactions in convenient and consistent formats that generate high content information. The company's lead line of products, the 3D Petri Dish®, is serving the needs of researchers in a wide range of areas including cancer research, stem cell biology, toxicity testing, developmental biology, drug discovery, regenerative medicine and tissue engineering. In addition to products for basic research, Microtissues® is using its platform technology to pursue applications in drug discovery and cell therapy. Need more information or for a sample please email us at info@microtissues.com...

Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minerva’s first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.

Diagnostics We build innovative diagnostic and monitoring tools that empower people to make better decisions about their health. Drug Discovery We translate early-stage research into customized RNAi and CRISPR Cas9 animal and cell models to accelerate drug development. Therapeutics We identify and validate new drug targets, unleashing the commercial potential of RNAi to benefit people on a global scale. Established in 2010 to harness the power of RNAi and genetic engineering technologies developed by our founders in the labs of the world's leading experts at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and Harvard Medical School, Mirimus creates innovative research and clinical technologies to address health issues on a global scale. Today, Mirimus markets multiple unique and high-value drug discovery and diagnostic products and services, and is advancing a pipeline of therapeutic candidates in partnership with leading biopharma companies to create novel high-impact health care solutions that benefits society on a global scale. Mirimus' ability to leverage its cutting-edge science and proprietary technology platforms to rapidly create new, affordable technology and products at scale is core to the way we work. We embrace diversity and creativity and have a proven track record of innovative problem solving—which led to our recognition as a $1M grand prize winner of the XPRIZE competition by developing a radically affordable, rapid, non-invasive methodology for mass COVID-19 testing—driving us to make better drugs and detect disease earlier. At Mirimus, our ingenuity, respect for our colleagues' ideas and creativity, executional agility, and a commitment to global health equity combine to create a unique culture of innovation that delivers measurable progress.

Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune system mapping platform is designed to identify potential treatments for neurodegenerative diseases such as ALS and FTD.

Founded in 2021 and based in San Francisco, Monomer Bio specializes in wet-lab productivity and automation software built for cell biology workflows. We aim to transform the landscape of scientific research by automating laboratory processes while capturing clean, well-structured data. We have delivered a number of automated cell culture solutions to customers working in the fields of drug discovery and cell and gene therapy. We also consult: whether you need help deciding what instruments to buy, need help getting your instruments and software to talk to each other, or need something custom-built (software or hardware), drop us a note at hello@monomerbio.com. We love deep dives with your biologists, engineers, technicians, or executive team.

Montana Medical Researchis a dedicated independent research center that specializes in the management and coordination of phase II-IV clinical research trials.

NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, by ensuring high cell viability required to advance cell-based research. We develop and deliver microfluidic based solutions that are affordable, compact, and easy-to-use. Our expanding portfolio of instruments and consumables enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

NellOne Therapeutics is passionate about its work to pioneer advances in the field of tissue regeneration, developed over the course of many years of scientific research and exploration. Our highly experienced team is committed to improving outcomes for millions of patients across the world, and creating a successful business that truly makes a difference.

NeuCyte is a biotech company focused on CNS drug discovery. Its SynFire® technology uses human iPSC-derived neurons to identify drug targets, test efficacy, and safety of novel compounds for neurological disorders.

Neural Stem Cell Institute is a regenerative medicine company that focuses on developing stem cell therapies for diseases of the nervous system.

Neuronascent (NNI) is a small corporation, that we believe has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, which is of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, has completed in first-in-human testing (Phase 1a), with no significate safety concerns for this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States.

Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company’s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders.

Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease. Additional pipeline programs center around a novel target with the potential to address multiple disease mechanisms and that has broad clinical application across neurodegenerative and peripheral inflammatory diseases. We are creating a sustainable pipeline for the company by utilizing a functional genomics discovery platform based on human cell lines to identify novel targets. Through our approach we seek to transform patient lives in meaningful ways.

Nuo Therapeutics, Inc. is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing. The Company’s flagship product, Aurix is a biodynamic hematogel derived from the patient’s own platelets and plasma, which is used at the point-of-care to jumpstart the natural healing process in a broad range of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure injuries.

Obatala Sciences offers contract research services and research products to laboratories in industry and in academia. Our clients include major pharmaceutical companies, US government entities, contract research organizations, non-profit organizations, and academic research laboratories. Our areas of expertise include obesity, diabetes, energy metabolism, musculoskeletal system biology, and wound healing. ObaCell™, a unique fat tissue model, is a great tool for disease modeling and drug screening. Obatala Sciences can provide data in various areas depending on your interest including proteomics, genomics, functionality, and adipokine secretion. We also have the capability of forming white or brown fat tissue upon request.

Oculogenex is a biopharmaceutical company founded and directed by an ophthalmologist retinal surgeon with patients in mind. It was founded out of passion and frustration shared with patients losing vision due to lack of therapeutic options. We have professional and scientific experience with retinal diseases, genetic variations in retinal and optic nerve diseases. We have built a team of experts in animal models of macular degeneration, antioxidant therapies for macular degeneration, medical and surgical treatments of retinal diseases and drug delivery methods. This specialized team has been built to utilize genetic engineering technology to improve vision for patients with degenerative eye diseases.

Oncolyze is developing therapeutics that exploit a novel mechanism of action for the targeted and selective lysis of cancer cells and cancer stem cells.

OpenCell Technologies™ is a leading innovative company developing a cutting-edge, continuous, scalable, non-viral, cell agnostic soft-poration transfection technology. Our breakthrough platform enables efficient continuous delivery of large cargos into challenging cell types, expanding the frontiers of cell engineering in Biopharma and Cell & Gene Therapy. With precise control at the single-cell level and high throughput, our OpenCell™ technology drives scientific discovery and enhances the effectiveness, affordability, and scalability of current cellular therapies. We empower researchers and clinicians to achieve remarkable advancements in biomedical science and clinical practice.

Opsis Therapeutics is a company focused on advancing the pipeline of cell replacement therapies targeting ocular diseases. Leveraging innovations in induced pluripotent cell (iPSC) generation, retinal cell differentiation, and functional biomaterials, Opsis Therapeutics is developing cell therapies for patients with dry age-related macular degeneration (AMD), inherited macular degenerations (IMDs) and inherited retinal diseases (IRDs). Founded in 2016, Opsis Therapeutics is a joint venture of FUJIFILM Cellular Dynamics and David Gamm, M.D., Ph.D., and is headquartered in Madison, Wisconsin.

Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one. Our manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling us to create proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy. Our talented team is driven by a passion for science and compassion for patients.

OrganaBio was founded in 2018 with the mission to become the hub for tissue sourcing, clinical sample processing and contract manufacturing services to support cell and gene therapy developers around the globe. At our core, we continually apply a data-driven approach with meaningful insights across our strategically located facilities to provide solutions to our clients where they need it most. Headquartered in Miami, Florida, OrganaBio delivers products and services that span the full development lifecycle – from proprietary tissue supply chains and cellular starting materials to expert development, testing, and other support services that expedite the path to clinical translation.

Organoid Therapeutics is developing organoid-based technologies to correct hormone deficiencies in patients and streamline drug discovery and toxicology testing in the lab.

The future of preclinical drug discovery is engineered tissue. The founders of OrganOmics have developed cutting-edge, live human brain tissue models derived from stem cells. They have partnered with the neurosurgeons to source patient-derived cancer tissue to induce a realistic cancer pathology. Their patented microfluidic platform automates the assay, detailing drug responses of thousands of tissues generating high-content data. This vast, cellular response data is processed through artificial intelligence to predict the clinical outcomes of each candidate drug.

Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.

OriGen Biomedical is a leading producer of cryopreservation and cell culture products. OriGen’s focus is to produce a range of products to support the treatment of cancer, genetic conditions, and other life-threatening diseases. OriGen Biomedical® products are designed with the patient and user in mind and we strive to maintain excellent customer service to ensure that patient care is the priority. OriGen is a growing, privately-held medical device manufacturer founded in 1997 and headquartered in Austin, Texas. Quality is the foundation of all product designs at OriGen, and each product is produced with the intention of improving patient health. OriGen is certified annually to ISO 13485 standards and regularly inspected by the FDA, MDSAP, ISO certification organizations, and our customers. Our European distribution center serves to reduce the time to patients by providing stock products for quicker turnaround times out of the Netherlands.

Building a Healthier Future Our mission is to improve the health, vitality, and longevity of human beings through bioengineering. Who We Are At Ossium, we believe that science is humanity’s best weapon in the fight against disease, and we embrace the challenge of mobilizing the world’s healthcare ecosystem to win that fight. In pursuit of this goal, we empower our employees, maintain the highest standards of excellence, and are a force for good. PRINCIPLES The values we live by Impact We are mission-driven and results-oriented. We believe that a healthier world is a better one and that our work should drive positive change. Truth Embracing the truth empowers us to learn from both our successes and our mistakes. We follow the data wherever it leads. Ownership We hold ourselves and each other to the highest bar. We care deeply about the work we do and know that even the smallest details can make a difference.

Papillon Therapeutics is a clinical stage biotechnology company advancing multi-systemic genetic medicines for diseases with neurologic, cardiac, and other tissue pathologies, including Friedreich's ataxia, Danon disease, and Alzheimer's disease. Inherited conditions often cause degeneration of multiple tissues throughout the body, inspring our approach to develop therapies that offer patients lifelong multi-systemic therapeutic benefit from a single treatment. Our clinical stage program, a gene modified hematopoietic stem and progenitor cell (HSPC) therapy for treatment of Cystinosis, reported positive data in a Phase 1/2 clinical trial and is being advanced by Novartis. Building on this success, we are advancing gene modified HSPC treatments for life threatening conditions with neurologic disease, including Friedreich's ataxia, Danon disease, and Alzheimer's disease. Funding awarded by the California Institute of Regenerative Medicine (CIRM) and NIH to our scientific founders totals over $30 million towards the Cystinosis, Friedreich's ataxia, and Danon disease programs.

Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant challenges of male infertility. We recognize the critical gap in male fertility treatment and are committed to helping people on their path to parenthood. Our innovative in-vitro spermatogenesis (IVS) technology is poised to transform the fertility landscape, offering new hope and innovative solutions to those struggling to conceive. Led by a team of world-renowned scientists and physicians, we are advancing research into clinical applications. Our mission is to make parenthood a reality for more families through ethical, scientifically advanced fertility solutions. Did you know? *1 in 8 couples struggle with infertility. *50% of in vitro fertilization (IVF) procedures fail. *50% of infertility is linked to men. *Male infertility treatment has been stagnant since 1992. Paterna is the first to develop a truly new treatment for male infertility since then. With a strong foundation in science and a commitment to innovation, Paterna BioSciences is uniquely positioned to lead the next generation of male fertility treatments. We are actively seeking funding to accelerate our clinical development and commercialization efforts, bringing our life-changing technology to families worldwide. We help make parenthood possible. Learn more at www.PaternaBio.com Contact us: info@paternabio.com A New Paradigm in Human Reproduction.

Pathways to Stem Cell Science promotes the advancement of stem cell science and regenerative medicine through the combined provision of contract research services and educational programs. The organization seeks to lower the barrier to working with stem cells by providing cost-effective support for customized scientific projects. Their education programs enable students of all ages, Pre-K to 12 and college to do hands-on work with stem cells, and provides them with the skills, inspiration, career education and professional experiences needed to forge successful bioscience careers. They also support public outreach and provide specialized industry training to professional scientists.

PBS Biotech aims to be the leading provider of innovative, single-use bioreactor systems specifically designed to address the unique challenges of cultivating shear sensitive cell types for cell therapy development. Our offering includes scalable, cost-effective disposable solutions designed to take you from benchtop R&D to large-scale cGMP manufacturing, and expert process development services to help solve cell culture challenges and accelerate your path to commercialization. To learn more, contact our sales team at sales@pbsbiotech.com or visit our website at www.pbsbiotech.com

Pelage is a clinical-stage regenerative medicine company developing novel treatments for hair loss, including androgenetic alopecia. Based on discoveries in stem cell biology made by Pelage's scientific co-founders, the company's novel approach is designed to reactivate dormant hair follicle stem cells and restore the body's ability to grow hair naturally.

Personal Cell Sciences is a Life Sciences company that specializes in developing and distributing personalized Adipose Derived Stem Cell based anti-aging, topical skin care products using individual's own stem cells.

Personalized Stem Cells, Inc. (PSC) is raising the standard of Stem Cell therapy. We are committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and patients.

Discover Phycin's pioneering solution for ocular injuries – a groundbreaking therapy derived from the miraculous world of algae! As a leading innovator in growth factor technology, we present an unparalleled approach to transform the treatment of corneal damage for both military personnel and the general public.

Pluristyx is a pioneering company at the forefront of stem cell technologies. With a mission to revolutionize the field of regenerative medicine, Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies. The company's proprietary platform, panCELLa, represents a transformative leap in stem cell research, offering enhanced freedom to operate and unparalleled potential for medical advancements at a significantly accelerated timeline. Operating from two cutting-edge North American sites, Pluristyx is dedicated to driving progress and innovation in the realm of stem cell therapies. In July of 2023 Pluristyx and panCELLa merged. Pluristyx offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, “off-the-shelf” iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.

Predictive Biologybrings together stem cell biology, high throughput screening and genetics to elucidate molecular mechanisms underlying compound response.

ProtoKinetix (PKTX) is a research and development company leading the way in cell survival solutions. Its patented anti-aging glycopeptide (AAGP) is a revolutionary discovery with incredible opportunity to shape the future of ophthalmology, dermatology, transplant support and biomanufacturing. Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide helps more cells survive longer and has the capability to change health care forever. With AAGP, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve. ProtoKinetix has harnessed a molecule found in nature with the power to transform lives and the future of health care. Founded in 2002, ProtoKinetix secured a patent for anti-aging glycopeptide (AAGP), a naturally-occurring molecule that regenerates cells for animals surviving in arctic temperatures. AAGP has gone through a series of tests in laboratories throughout Europe and North America conducted by some of the best researchers in the world. Backed by a decade of promising clinical research, all trials to date have shown that AAGP is safe, stable and effective in protecting and regenerating cells. This molecule could be the link to improved treatments for transplants, Type 1 diabetes, macular degeneration, stroke, heart disease and so much more. There is endless potential, and we’ve only seen the tip of the iceberg. Become part of the next great medical discovery.

PurCell Bio is an innovative cell culture research company located in Bozeman, MT. We have developed a line of cell culture media and media supplements that surpass the growth performance of serum and Essential 8. Our products solve many of the major problems associated with serum use, like batch to batch variability, contamination concerns, and high cost. For more information, please visit our website. Our vision is that PurCell's products will initiate an industry-wide exodus from animal-based products to chemically-defined alternatives. This shift will remove tremendous barriers for cellular-based therapies entering clinical trials and facilitate more effective research around the world.

Q Therapeutics is a biotechnology company based out of 417 S Wakara Way, Salt Lake City, UT, United States.

At Reagents Direct, it is our mission to make quality reagents easily accessible to your lab. Reagents Direct is a small company that focuses our attention on you. We search for the important and upcoming reagents in the fields of cell biology, stem cell biology and biochemistry and get them directly to you as fast as possible. We take the effort out of searching for the best-priced reagent and show you all your options. Our mission is to bring quality reagents to our customers, when they want them. Once you get our reagents in your lab, we provide in-depth information on our product specification sheets, as well as detailed information on our website. We provide usage information, publications and insider tips from other scientists using our products. Reagents Direct should be your one stop to find all the information you need in order to use our reagents in your lab.

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

High-Throughput Screening Platforms

Regenerative Patch Technologies LLC (RPT) is a CA-based biotechnology company focused on the development of stem cell-based therapies designed to reverse blindness caused by advanced dry age related macular degeneration (AMD).

Regeneris Medical is a healthcare and clinical research organization specializing in regenerative medicine and cellular therapies. We are driven by our mission to transform people’s lives by providing tomorrow’s healthcare today. Currently, research-level therapies such as PRP (Platelet Rich Plasma) and SVF (Stromal Vascular Fraction) are used to treat a variety of medical and aesthetic conditions including hair loss, arthritis, spine disease, joint pain, lupus, interstitial cystitis, multiple sclerosis, muscular dystrophy, ALS, Parkinson’s disease and stroke recovery.

Welcome to Regenicin specializing development regenerative cell therapies, NovaDerm®

Collagen Matrix is now Regenity Biosciences. Regenity Biosciences advances new frontiers in regenerative science, turning bioabsorbable materials into life-changing solutions. Sought after for our novel resorbable technologies and distinct approach to contract manufacturing and contract development, our team brings the urgency and vision to deliver breakthrough medtech solutions for medical technology and medical device manufacturers of all sizes. Company Background For more than 25 years, Regenity Biosciences has been transforming bioabsorbable materials into regenerative solutions to repair and regenerate tissue and bone we have since introduced numerous bioresorbable technologies with more than 71 product lines commercially available worldwide. Most recently, Regenity expanded its product portfolio to include versatile bioresorbable polymer technologies via the acquisition of Polyganics, which was the impetus behind the new name and brand direction. Regenity is headquartered in Paramus, New Jersey, with manufacturing locations in Oakland and Allendale, New Jersey and Groningen, the Netherlands. Mission & Values Every day, we work to make a material difference in the lives of patients. With people’s health on the line, it’s our duty to act with urgency and diligence. It is this collective ethos that drives us each day to push the boundaries of what’s possible in tissue repair and regeneration. Looking for a Career with Purpose? Join our team and work with us to develop life-changing products that help patients heal. Visit our website to learn more about what sets Regenity apart. www.Regenity.com CMIContact@CollagenMatrix.com

Renovaro Biosciences, Inc. is a biotechnology company committed to developing advanced allogenic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as HIV and Hepatitis B virus (HBV) infection.

RenOVAte Biosciences Inc (RBI) is a Delaware Incorporated, Maryland based animal biotechnology company founded in December 2016. RBI is in the business of performing sophisticated and precision genome editing and genetic engineering in livestock species, to address critical priorities of animal and human health.

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and reprogramming biology.

Aspiring to add 10 years to healthy human lifespan, starting with cellular reprogramming, autophagy, & plasma-inspired therapeutics

Rocket Pharmaceuticals (NASDAQ: RCKT), Ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. We are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based and adeno-associated virus (AAV) therapy approach. We have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. Ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need.

Ronawk's Bio Block Universe is the first expandable Bio Platform from which other applications, processes, and technologies are developed. Ronawk's Bio Block Universe accelerates time to result by eliminating the need for sub-culture in cell production which subsequently decreases contamination risks and increases cell yield. Ronawk's Bio Block Universe transforms what was once tedious to effortless by simplifying cell culture workflows through the reduction of labor, materials, and space. Ronawk's Bio Block Universe increases biological opportunities by recapitulating the native cell environment to maintain cell viability, key characteristics, and secretion of therapeutic biologics.

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and exosome/extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and exosome production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type II Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by our client's success and creating a world where safe and effective advanced therapies are rapidly developed and widely available on a global scale.

Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases. The company's mission is to fast-track the early stage of drug discovery using predictive models of the human brain for therapeutic success.

RxCell is a biotechnology company that specializes in the development of advanced cell-based therapies for the treatment of various diseases and medical conditions.

Safi Biotherapeutics is an early stage biotech company developing cell therapies from hematopoietic progenitor sources.

Samsara Therapeutics, Inc. is biopharmaceutical company aiming to discover first-in-class therapeutics that treat rare genetic and neurodegenerative disease, and extend healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy. Samsara Therapeutics is a global biotech company with operations in Oxford and Boston and significant academic collaborations in Paris and Graz

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

SanBio, Inc. - Founded in February 2001 SanBio's scope of business is development, production and sales of regenerative cell medicines. Our mission is to develop regenerative medicines, creating benefits for patients and value for stakeholders. Our vision is to achieve global leadership in the regenerative medicine field using best science and technology, building global revenues and sponsoring successful clinical trials. SanBio focuses on using regenerative cell medicine to treat the disabilies caused by diseases of the central nervous system. Most of these conditions currently have no effective medicinal treatment, and those treatment that do exist generally address disease symptoms and not the underlying cause of the disease. Such conditions afflict a vast number of patients worldwide.As of January, 2016, SanBio had introduced a product for the treatment of chronic motor impairment from ischemic stroke and traumatic brain injury into clinical development in both Japan and the US. In the future, SanBio plans to continue expanding the indications and geographical regions for its products, using both internal development, as well as partnerships and licenses.

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding basic human biology and disease and advancing scientific discoveries to profoundly impact human health. Our track record of pioneering research spans more than 40 years and has produced breakthroughs in cancer, neuroscience, immunology and children's diseases and is anchored by our NCI-designated Cancer Center. Sanford Burnham Prebys' drug discovery center and global partnerships propel our prototype drugs and therapeutic strategies toward improving human health. A deep culture of collaboration and commitment to educating the next generation of scientists unites Sanford Burnham Prebys researchers, partners and philanthropists in a shared mission to improve human health.

San Rocco Therapeutics is a biotechnology company with its primary focus on curative gene therapies for Sickle Cell Disease and Thalassemia

ScienCell Research Laboratories is an expanding biotechnology company established in 1999. Our mission is to research and develop cell products for experimental and therapeutic use. ScienCell provides a variety of high quality normal human and animal cells, cell culture media and reagents, gene analysis tools, cell-derived molecular biology products, cell-based assay kits, and stem cell products for the research community. To complement our vast array of primary human and animal cells, we offer specialty medium designed to selectively promote unique cell growth, including STEMium™, which allows for the optimal growth of human pluripotent stem cells under feeder-free conditions. The Scientists at ScienCell are studying and developing cell therapeutic strategies to significantly improve the quality of life for patients with degenerative diseases.

Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies. Our highly pure insulin-producing cells are micro-encapsulated through a proprietary technology that enables the function of human pancreas cells in type-1 diabetes models without the need for immuno-suppression. Seraxis intends to bring SR-01 to the clinic in order to provide a cure for the devastating disease of diabetes.

Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.

Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.

Simnova is a clinical stage biotech company focusing on the development of first/best-in-class cell therapy for cancer treatment.

Stelexis is a Deerfield founded and solely funded New York-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the discovery and development of novel drugs. Stelexis proprietary platform is focused on identifying, isolating and studying the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations, that drive the formation of primary and recurrent human tumors. Stelexis utilizes this powerful platform as a target identification engine and drug discovery and development tool to address unmet needs in multiple cancer indications. Deerfield founded Stelexis Therapeutics in 2017 together with scientific founders, Drs. Ulrich Steidl, Evripidis Gavathiotis, Amit Verma and Roman Perez-Soler of Albert Einstein College of Medicine, Montefiore Medicine, New York and Dr. Derrick Rossi of Boston Children’s Hospital, Harvard Medical School.

StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. We are currently focused on scale-up activities for our patented core technology, CELLvo™ Matrix and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. Our core novel technology platform is an advanced stem cell culture system – CELLvo™ Matrix. CELLvo Matrix™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality.

StemCellerant designs and manufactures stem cell based research tools and therapeutics with a mission to accelerate personalized regenerative medicine.

Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. More information on Stemedica may be found at www.stemedica.com.

At Stemson Therapeutics, we envision a world where anyone battling the emotional trauma or social stigma of hair loss has an opportunity to truly cure their condition and safely restore their natural hair.

Sudhin Biopharma Co. is a biotechnology company developing efficient continuous biological manufacturing processes for therapeutic biologicals, sweet proteins, cell therapies and biological roducts.

Sunny Biotechnology Co focuses on the development of polyclonal, monoclonal, secondary antibodies, serum-free media and supplements for stem cell research, peptide synthesis service, and related biotech products for life science research and clinical diagnosis.

SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.

Syntax Bio is a preclinical-stage biotech company, overcoming longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.

At SBI, our mission is to accelerate your science by turning the latest insights and technologies into robust research products and services to advance exosome studies, biomarker research, gene delivery, SARS-CoV-2 studies, and more.

Tachyon is accelerating innovative science to develop first-in-class therapeutics against significant new drug targets in cancer biology. Tachyon operates with a dedicated internal core development team and a world-class external network of expertise to achieve one goal - advance our programs with speed, innovation, quality and scientific integrity.

Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach.

The company is developing a ventricular shunt, for children with hydrocephalus.

Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy and regenerative medicine. The Company’s clinical-grade fucosyltransferase enzymes and small molecule products (TZ101 and TZ102) are off-the-shelf biologic products used at the point-of-care to treat therapeutic cells immediately before infusion into the patient using a simple procedure that is easily incorporated into existing medical practice. The Company has received worldwide patents, multiple FDA orphan drug designations, has an open investigational new drug application (IND) with multiple ongoing clinical studies and a Phase 3 Special Protocol Assessment (SPA) with the FDA. Targazyme’s fucosylation technology has received numerous medical and scientific awards from institutions such as NIH, NCI, US Treasury, CPRIT, ETF, OCAST, JDRF, Leukemia, Lymphoma Society. Targazyme has partnerships and collaborations with Kyowa Hakko Kirin and Florida Biologix, as well as various medical research institutions including The University of Texas M.D. Anderson Cancer Center, Oklahoma Medical Research Foundation, Texas Transplant Institute, Case Western/University Hospitals, Scripps Hospitals, Fred Hutchinson Cancer Research Center, University of California Los Angeles Medical Center, Stanford University Medical Center, University of Minnesota Medical Center, University of California San Diego Medical Center, Sanford-Burnham Medical Research Institute, Indiana University, Memorial Sloan Kettering Cancer Center, and New York Blood Center. Learn more at http://www.targazyme.com.

Telios Pharma, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in developing therapies for mast cell-mediated inflammatory diseases. Founded in 1993, the company focuses on small-molecule drugs and has a team of 51 to 100 employees. Its annual revenue is estimated between $10 million and $25 million. The company's pipeline includes innovative Bruton’s tyrosine kinase (BTK) inhibitors. Notable candidates are TL-925, a topical eye drop for dry eye disease currently in Phase 2 trials, and M-7583, an oral BTK inhibitor for primary myelofibrosis. TL-925 has shown promising results, providing rapid relief from symptoms and significant improvements in clinical measures. Telios Pharma aims to address significant unmet needs in both dry eye disease and myelofibrosis, targeting markets with limited existing therapies.

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on developing Telomir-1 as the first novel small molecule to lengthen telomeres, which are protective structures at the ends of chromosomes that play a key role in cellular aging and disease. The company is dedicated to the development and commercialization of therapeutic products for the treatment of age-related diseases and conditions.

Tempo Bioscience is a biotechnology company that develops human stem cells based disease models and biosensor enabling technologies for various applications.

Tempo Therapeutics is a biotechnology company that specializes in tissue engineering using proprietary MAP material science technology to build functional tissue and organs within patients in real time for disease treatment.

Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.

Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health.

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thymmune is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases. Thymmune is based in Cambridge, MA.

Adipose Cell Isolation

Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies.

Trailhead Biosystems merges developmental biology and cell therapeutics with cutting edge hardware, and computerized experimental design and analysis to perform process-specific parameter optimization for customers seeking to develop cell therapies. Implementing Quality by Design (QbD) principles, cell culture optimization is done by utilizing Design of Experiment (DoE) theory combined with Multivariate Data Analysis (MVDA). This allows Trailhead to generate mathematical models of the biological system, understand the effector-response relationship in cell culture, and provide a systems biology analysis of the differentiation space. DoE-based experimental design and robotic execution greatly reduce the number of experiments and time needed for optimizing a large number of variables simultaneously. You will see that Trailhead Biosystems is novel from its ability to: Have computer-based experimental designs executed for advanced cell culture Gain knowledge into how cell culture affects gene expression in cells Mathematically model the effector/response space so virtual experiments can be performed and enable exploration of cell biology to predict how additives will create desirable cell culture fates Address optimization challenges for cell purity and potency Understand the variance in cell manufacturing methods

Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs.

We are a biotechnology company focused on restoring cells’ youthful vigor to repair damage caused by the aging process. Using a proprietary ERA™ Platform, we develop mRNA medicines that are specially formulated to instruct specific cells in the body to fight disease or repair damaged tissue. We do this by reprogramming the epigenome to restore cell function that people often lose as they age. This approach can be used to revitalize different cells throughout the body – we are researching its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis and ophthalmology.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

U.S. Stem Cell, Inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. The company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product AdipoCell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. In the past 20 years, to the company’s knowledge, U.S. Stem Cell, Inc. has completed more clinical treatments than any other regenerative care provider in the world. With more than 700 physicians trained and certified with the company, U.S. Stem Cell, Inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

U.S. Stem Cell, Inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. The company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product AdipoCell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. In the past 20 years, to the company’s knowledge, U.S. Stem Cell, Inc. has completed more clinical treatments than any other regenerative care provider in the world. With more than 700 physicians trained and certified with the company, U.S. Stem Cell, Inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

Vala Sciences helps researchers achieve an unrivaled in vitro understanding of how human cells respond to drug compounds. Vala is committed to providing expert services to pharmaceutical developers and researchers to help overcome the persistent challenge of reducing avoidable clinical failures of drug candidates in the following areas: Cardiac biology: By precisely measuring up to three channels (voltage, calcium, and contractility) of single-cell hiPSC-cardiomyocyte kinetic data in real time and comparing cell responses with known healthy or disease-model cells, Vala can help rank order drug candidates by identifying toxicities, dose response, and efficacy. Neuroscience: Vala has developed co-culture assays with hiPSC-neurons, -microglia, and -astrocytes for neurodegenerative disease drug discovery and toxicity screening. By measuring voltage and calcium kinetics, neurite and synapse formation, and engulfment by microglia, Vala can provide a detailed picture of disease mechanisms and treatment efficacy. Vala Sciences develops and manufactures the Kinetic Image Cytometer (KIC®) and Structured Illumination Microscopy (SIM) platforms, which enable information-rich measurements for making new insights into the cell biology of disease. CyteSeer®, our cell image analysis software, can resolve billions of single-cell data points from fixed or live cells. Vala’s toolset allows researchers to perform accurate, cost-effective screens for drug candidates with high probability of clinical success and low probability of side effects. We provide varied and validated high content screening services that quantify the effects of compound libraries on a number of target molecules. Vala is a registered supplier on Scientist.com. Visit our profile here: https://app.scientist.com/domain_switcher?redirect=/providers/vala-sciences

Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).

Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow, particularly for those patients at high risk for amputation and death for whom few to no treatment options remain. The company’s lead product is an allogeneic vasculogenic cell – a cell with the potential to forge new blood vessels in oxygen-starved tissues. The vasculogenic cell product is manufactured from induced pluripotent stem cells (iPSCs), which provide a limitless source from which to produce off-the-shelf, cryopreserved doses at scale.

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Our team is committed to leveraging ARMMs technology to enable new therapies and address currently unmet medical needs.

VetStemprovides veterinarians and owners with a way to treat dogs, horses and cats with the animal's own stem cells.

Our Mission: To provide the highest-quality stem cell preservation service and care to our patients, families, and their physicians. We at ViaCord believe these words are much more than just a promise. They are the commitment we live by. Our Origins: ViaCord was established in 1993 to give expectant parents an opportunity to bank their children's cord blood with comfort and security. Prior to launching our Cord Blood Banking Service, ViaCord conducted extensive research and validation studies to set high standards regarding the collection, processing, and storage of cord blood. ViaCord worked closely with the following institutions during our development: * Obstetrics Program at Brigham and Women's Hospital in Boston, MA * The Christ Hospital in Cincinnati, OH * The University of Cincinnati's Hoxworth Blood Center, OH ViaCord's headquarters are located in Cambridge, Massachusetts; a recognized global hub of biotechnology. All cord blood collections are processed and stored at our cord blood storage facility outside of Cincinnati.

Visicell Medical Inc. was founded by a team of passionate scientist, engineer, and radiologist with a singular goal: to help accelerate stem cell-based therapy to the market for patients who are afflicted with devastating and currently incurable diseases. Our technology platform will transform how biopharmaceutical products are developed and taken to market by offering customers clinically applicable imaging tools that can provide real-time insights for their unique individual research needs.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company’s CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

Vita Therapeutics - We are a team of dedicated scientists striving to advance treatments in multiple indications in our cell therapy platform. Our mission is to utilize the power of genetics to deliver life-transformative cell therapies by unlocking the potential of engineered cellular medicine.

We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.

As a recognized world leader in pluripotent stem cell banking and characterization, WiCell provides the stem cell community with high-quality cell lines as well as accurate and reliable cell characterization and cytogenetic testing services. We offer both cGMP and research grade services and cell lines to fit your lab's needs. In addition, WiCell offers affordable and reliable long-term LN2 storage through our WiCellSAFE program to safeguard and protect your research investment.

Xēnix Medical is a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery. The company, headquartered in Orlando, Florida, markets its line of spinal implant devices in the United States through a network of independent distributors.

Mixed Lymphocyte Reactions are cell proliferation assays. We offer a comprehensive selection of MLRs experiments to test your product.

ZenBio is a provider of advanced cell-based solutions and services to the life science, cosmetics, and personal care communities, specializing in adipose derived stem cells and human primary cells.